Title

The percentage of Monocytes CD39+ is higher in Pregnant COVID-19 than in Non-Pregnant COVID-19 patients

Running title

Immune profile in pregnant women with COVID-19

Authors and institutional affiliations

A. Crbulo-Vzquez¹, M. Garca-Espinosa², J.C. Briones-Garduo³, L. Arriaga-Pizano⁴, E. Ferat-Osorio⁵, B. Zavala-Barrios³, G.L. Cabrera-Rivera⁴, P. Miranda-Cruz⁴, M.T. Garca de la Rosa⁴, J.L. Prieto-Chvez^{4,6}, V. Rivero-Arredondo⁴, R.L. Madera-Sandoval⁴, A. Cruz-Cruz⁴, E. Salazar-Rios⁴, ME Salazar-Rios⁴, D Serrano-Molina⁴, R. C. De Lira-Barraza⁴, A. H. Villanueva-Compen⁷, A. Esquivel-Pineda⁷, R. Ramirez-Montes de Oca⁷, F. Caldio-Soto⁸, L.A. Ramrez-Garca⁹, G. Flores-Padilla⁷, O. Moreno-lvarez¹⁰, GML Guerrero-Avendao¹¹ and C. Lpez-Macas^{4,12} *

¹Departamento de Medicina Genmica, ³Direccin de Medicina Aguda, Diagnstico y Tratamiento, ¹¹Direccin General. Hospital General de Mxico "Dr. Eduardo Liceaga". Ciudad de Mxico, Mxico

²Servicio de complicaciones de la segunda mitad del embarazo, ⁸Divisin Obstetricia.

⁹Direccin Mdica, ¹⁰Direccin General. UMAE Hospital de Gineco-Obstetricia No. 4 "Dr. Luis Castelazo Ayala". Instituto Mexicano del Seguro Social (IMSS). Ciudad de Mxico, Mxico

⁴Unidad de Investigacin Mdica en Inmunoqumica, ⁵Divisin de Investigacin,

⁶Centro de Instrumentos, ⁷Medicina Interna. UMAE Hospital de Especialidades, Centro Mdico Nacional Siglo XXI. IMSS. Ciudad de Mxico, Mxico

¹²Visiting Professor of Immunology, Nuffield Department of Medicine. University of Oxford U.K.

*Corresponding authors: A. Crbulo-Vzquez and C. Lpez-Macas.

e-mail: cerbulo@unam.mx; constantino@sminmunologia.mx; constantino.lopez@imss.gob.mx

* Corresponding authors: Phone: (+52 55) 5627 6915

Keywords: COVID-19, pregnancy, immunophenotype, cytokine, chemokine.

39 **Abstract**

40 Current medical guidelines consider COVID-19 pregnant women a high-risk group.
 41 Physiological gestation down regulates the immunological response to maintain
 42 “maternal-fetal tolerance”; hence, a SARS-CoV-2 infection constitutes a potentially
 43 threatening condition to both the mother and the fetus. To establish the immune profile
 44 in pregnant COVID-19+ patients a cross-sectional study was conducted. Leukocyte
 45 immunophenotype, mononuclear leukocyte response to polyclonal stimulus and
 46 cytokine/chemokine serum concentration were analyzed in pregnant fifteen COVID-
 47 19+ and control groups (fifteen non-pregnant COVID-19+, and thirteen pregnant
 48 COVID-19- women). Pregnant COVID-19+ patients exhibit lower percentages of
 49 monocytes HLA-DR+ compared with control groups. Nevertheless, pregnant COVID-
 50 19+ women show a higher percentage of monocytes CD39+ than controls. Furthermore,
 51 a higher concentration of TNF- α , IL-6, MIP1b and IL-4 was observed within the
 52 pregnant COVID-19+ group. Our result shows that pregnant women express
 53 immunological characteristics that potentially mediate the immune response in COVID-
 54 19.

55

56 **Introduction**

57 The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East
 58 Respiratory Syndrome Coronavirus (MERS-CoV) infections could result in a high
 59 mortality among pregnant women (25% and 27%, respectively) (1). In 2019, a new
 60 coronavirus called SARS-CoV-2 appeared. Viral infections lead to a powerful cell and
 61 humoral immune response in gestating women, increasing the embryo/fetal-mother
 62 morbidity and mortality (2-4). The immune response in pregnant women is mediated by

a diverse number of cellular and humoral mechanisms (5, 6) that result in a unique biological scenario that these women face when infected with SARS-CoV-2. Moreover, comorbidities highly prevalent in Mexico, such as obesity, hypertension and diabetes are associated with critical disease in both general population and pregnant women (3, 4, 7, 8). However, the clinical presentation and symptoms are quite similar between the general population and pregnant women COVID-19+ (3, 9).

In contrast to the epidemiological and clinical evaluation, the immune profile of pregnant women with COVID-19 has been poorly explored. Similar to the general population, deep lymphopenia is reported in pregnant women with COVID-19 (10). Other parameters, such as neutrophil count, are useful for a COVID-19 diagnosis (11). Furthermore, an increased number of neutrophil/lymphocyte ratio has been associated to a fatal outcome in COVID-19 patients (12-15). Several studies indicate that leukocyte count is necessary for the initial evaluation of COVID-19 patients. However, a deeper analysis of these leukocytes could improve our knowledge of the SARS-CoV2 infection, especially in pregnant women.

Cytokines and chemokines are key regulators in the coronavirus infection. SARS-CoV induces low expression of IFN- α , IFN- β and IL-10, as well as a moderate expression of TNF- α and IL-6 and a high expression of CCL3, CCL5, CCL-2 and CXCL10 (16) (17).

In addition, SARS-CoV's protein S induces CCL2 and CXCL8 synthesis *in vitro* (18, 19). Also, several humoral components of the immune response are involved in COVID-19, among them, inflammatory cytokine/chemokines which have been observed in high serum concentrations at the general population (20, 21). COVID-19 patients show a higher concentration of IL-2, IL-7, IL-10, G-CSF, IP10 (CXCL-10), MCP-1 (CCL2), MIP1a (CCL3) and TNF- α compared to non COVID-19 patients (20).

87 The source of these cytokine/chemokines is diverse, and could include lung epithelial
88 cells, endothelium cells, and leukocytes (22-24).
89 Exacerbated inflammatory response in pregnancy could disturb the delicate immune
90 balance, leading to a significant increased morbidity and mortality. To analyze the
91 immune profile in pregnant women with COVID-19+, a cross sectional study was
92 executed. Our analysis includes a) immunophenotype of lymphocytes and monocytes
93 expressing certain activation markers, b) serum cytokine/chemokine concentration, and
94 total blood challenged against polyclonal stimulus, in presence or absence of Brefeldin-
95 A, after 4 hours of culture, c) inflammatory cytokines determination, and d) supernatant
96 cytokine/chemokine concentration. A more detailed picture of the immune map in
97 pregnant women with COVID-19 could help better understand the pathophysiology of
98 SARS-CoV-2 infection and improve the quality of healthcare provided to these women
99 and newborns.

100

101 **Material and methods**

102 **Patients**

103 This study was conducted by the "Servicio de Ginecología y Obstetricia" at the Hospital
104 General de Mexico, "Dr. Eduardo Liceaga" in conjunction with the Unidad de
105 Investigación Médica en Inmunoquímica (UIMIQ), at the Hospital de Especialidades,
106 Centro Médico Nacional Siglo XXI, and Servicio de complicaciones de la segunda
107 mitad del embarazo, División Obstetricia. UMAE Hospital de GinecoObstetricia No. 4
108 "Dr. Luis Castelazo Ayala" (Research project: *DI/20112/04/45*, and *R-2020-785-095*
109 respectively). After obtaining a signed informed consent letter, forty-four women were
110 enrolled. Three groups were analyzed: a) Non-pregnant COVID-19 positive (NP-

COVID-19+, n=15), b) Pregnant COVID-19 positive (P-COVID-19+, n=16), and c) Pregnant COVID-19 negative (P-COVID-19-, n=13). SARS-CoV2 viral infection was confirmed by specific reverse transcription–polymerase chain reaction (RT-PCR). The COVID-19 diagnosis was based on clinical characteristics (25); comorbidities and clinical signs or symptoms were registered and shown in Table 1 and 2 respectively.

Blood sample collection

Our study is in accordance with the World Medical Association’s Declaration of Helsinki. After a patient agrees to participate in the study, healthcare personnel collected blood specimens in silicone coated, EDTA and heparinized tubes (BD Vacutainer, N.J, USA). Samples were processed immediately after collection. Whole blood count and serum was obtained to compare among groups.

Leukocyte surface immunophenotype

Whole blood samples (50 µL) were incubated with titrated volumes of antibodies according to the following panel: all antibodies were from BioLegend, San Diego, CA, USA. Anti-CD45-PerCP (Clone:HI30), anti-CD3-AF647 (Clone:UCHT1), anti-CD14-PECy7 (Clone:M5E2), anti-CD16-FITC (Clone:3G8), anti-CD19-APC/Cy7 (Clone:HIB19), anti-CD73-PE (Clone:AD2), anti-CD39-BV421 (Clone:A1), anti-CD4-APC/Cy7 (Clone:OKT4), anti-CD8-PE/Dazzle594 or BV510 (Clone:SK1), anti-CD69-BV421 (Cone:FN50), anti-HLA-DR-AF488 o PE/Dazzle594 (Clone:L243), and for exclusion of dead cells Zombie Aqua fixable viability kit (BioLegend, San Diego, CA, USA) were used. After 15 minutes of incubation, erythrolysis was performed using FACS™ Lysing Solution (Cat. 349202, BD, San Jose, CA, USA). Samples were washed once with PBS 1x (1,500 rpm, 5 minutes, 4°C), and resuspended in PBS (100 µL). At least 30,000 leukocytes were acquired in a FACS Aria IIu flow cytometer (BD

135 Biosciences, San José, CA, USA). The FACS files were analyzed with Infinicyt™
136 software 1.8 (Cytognos, Salamanca, Spain). Single cells were defined with FSC-A vs.
137 FSC-H plot, and leukocytes were identified using a SSC vs. CD45 plot. Lymphocytes
138 were gated as SSC^{low}FSC^{low}CD45⁺⁺CD14⁻, monocytes as SSC^{mid}FSC^{mid}CD45⁺CD14⁺,
139 and granulocytes-neutrophils as SSC^{mid}FSC^{mid}CD45⁺CD16⁺. Percentage and mean
140 fluorescence intensity (MFI) of HLA-DR, CD69, CD39, CD73, CD32 and CCR5
141 positive cells were calculated.

142 **Cell culture**

143 Whole blood (1 mL per well) was incubated (4 hours at 37°C with 5% CO₂) alone in
144 24-well culture plates (Cat 13485, Costar, NY, USA), in the presence of human
145 recombinant IL-6 (human rIL-6, 100 ng/mL), *Escherichia coli* O55: B5
146 Lipopolysaccharide (LPS 250 ng/mL, Cat. L2880, Sigma Aldrich, St. Louis, MO,
147 USA), or Phorbol Myristate Acetate/Ionomycin (PMA 50 ng/mL, Ion 1mg/mL). In
148 addition, two sets of samples were incubated, in the presence or absence of Brefeldin-A
149 (Cat. 420601, BioLegend, San Diego, CA, USA). Afterwards, either intracellular
150 phenotyping was performed, or supernatant was recovered and stored at -20°C until
151 cytokine and chemokine assessment.

152 **Intracellular cytokine immunophenotype**

153 After cell culture, whole blood samples (50 µL) were incubated with the following
154 panel: antibodies from BioLegend, San Diego, CA, USA: anti-CD45-PerCP (Clone:
155 HI30), anti-CD3-AF647 (Clone: UCHT1), anti-CD14-PECy7 (Clone: M5E2), anti-
156 CD4-APC/Cy7 (Clone: OKT4), anti-CD8-PE/Dazzle594 or BV510 (Clone: SK1). After
157 15 min in the dark, blood was washed once with PBS (1mL) by centrifugation at 900×g
158 for 5 min at RT, then Fixation buffer was added (100 µL, Cat: 420801, BioLegend, San

159 Diego, CA, USA), and incubated for 20 min. Samples were then washed twice with 1
160 mL of Intracellular Staining Perm Wash buffer (Cat: 421002, BioLegend, San Diego,
161 CA, USA); after the second wash, they were mixed with monoclonal antibodies against
162 cytokines from BioLegend, San Diego, CA, USA: anti-TNF α -BV421 (Clone: MAb11),
163 anti-IL-6-PE (MQ2-13A5), anti-IL-1 β -FITC (Clone:JK1B-1), anti-IFN γ -BV421
164 (Clone:4S.B3), anti-IL-8a-PE (Clone: E8N1). For the exclusion of dead cells Zombie
165 Aqua fixable viability kit (BioLegend, San Diego, CA, USA) was adjoined and
166 incubated for 30 min dRT. Lastly, the mixture was washed once with PBS. At least
167 30,000 events were acquired in a FACS Aria IIu (BD, San Jose CA) flow cytometer.
168 Analysis was performed using the Infinicyt™ Software 1.8.

169 **Serum or supernatant cytokine/chemokines concentration**

170 Serum or cell culture supernatant was analyzed as follows; cytokines (IL-2, IL-4, IL-6,
171 IL-10, TNF- α , IFN- γ , and IL-17a) and chemokines (CXCL8/IL-8, CXCL10/IP-10,
172 CCL11/Eotaxin, CCL17/TARC, CCL2/MCP-1, CCL5/RANTES, CCL3/MIP-1a,
173 CXCL9/MIG, CXCL5/ENA-78, CCL20/ MIP-3a, CXCL1/GRO α , CXCL11/I-TAC and
174 CCL4/MIP-1b) were determined using bead based immunoassays (CBA kit, Cat.
175 560484, BD PharMingen, San Diego, CA, USA; and LEGENDplex, Cat. 740003,
176 BioLegend, San Diego, CA, USA). Log-transformed data were used to construct
177 standard curves fitted to 10 discrete points using a 4-parameter logistic model. The
178 concentration of each cytokine/chemokine was calculated using interpolations of their
179 corresponding standard curves.

180 **Statistical analysis**

181 Statistical analysis was performed using GraphPad Prism® version 7 software
182 (GraphPad Software, San Diego, CA, USA). Non-parametric ANOVA test (Kruskal-

183 Wallis test) with Dunn post-test were applied. Categorical variables were expressed as
184 percentage number (%) and compared by Fisher's exact test. A $p < 0.05$ was considered
185 as statistically significant.

186

187 **Results**

188 To assess the immune profile in pregnant women infected with SARS-CoV-2, we
189 analyzed; a) NP-COVID-19+, b) P-COVID-19+ and c) P-COVID-19-. Table 1 shows
190 the clinical characteristics and laboratory values. No statistically significant difference
191 was observed for age, BMI, respiratory rate, body temperature, Mean Arterial Pressure
192 (MAP), hemoglobin, total leukocyte count, Neutrophil/Lymphocyte Ratio (NLR), total
193 platelet count, serum glucose, serum creatinine, Partial Thromboplastin Time and
194 fibrinogen between the NP-COVID-19+ or P-COVID-19- groups vs. P-COVID-19+.
195 We did not observe any difference in the leukocyte count among groups, this is
196 consistent after phenotyping analysis by flow cytometry (Table S1). Furthermore, the
197 frequency of comorbidity (diabetes mellitus and systemic arterial hypertension) was
198 similar among the groups. On the other hand, some clinical characteristics display
199 differences, for example, heart rate was higher in P-COVID-19+ than in P-COVID-19-
200 patients ($p = 0.048$). Likewise, serum Lactate Dehydrogenase (LDH) concentration was
201 higher in P-COVID-19+ than in P-COVID-19- group. Nevertheless, patients in the P-
202 COVID-19- group maintain higher oxygen saturation levels than in COVID-19+
203 patients with or without pregnancy. Regarding serum D-dimer concentrations, higher
204 magnitudes were reported in P-COVID-19+ than in NP-COVID-19+. It is worthy of
205 highlighting that a SARS-CoV-2 infection does not increase the D-dimer concentration

206 to the levels reported in physiological pregnancy. Similar gestational age, and number
207 of cases per trimester were analyzed in pregnant women.

208

209 **Table 1. Clinical and laboratory characteristics.**

	NP-COVID-19 + (n=9-15)a	P-COVID-19 + (n=8-15)b	P-COVID-19 - (n=13)c	<i>p</i>
Age (years)	34.1±7	28±7.1	25.6±5.7	a vs. c 0.006
BMI	31.6±6.9	30.0±6.3	28.0±3.5	0.356
Respiratory Rate (breaths per min)	23±3.8	22.1±6.8	18.6±1.1	a vs. c 0.005
Heart Rate (beats per min)	91.2±25.1	97.3±19.6	77.7±7.5	b vs. c 0.048
Temperature (°C)	36.9±1.2	36.7±0.7	36.3±0.2	0.081
Mean Arterial Pressure (mmHg)	159.5±17.4	153.2±15.4	157.1±13.3	0.631
Hemoglobin	13±2.7	12.6±2.0	11.9±1.1	0.070
Leukocytes (10xmm³)	8.6±4	11.1±3.2	8.4±2.3	0.140
NLR	11.8±11.7	5.1±1.9	3.7±1.2	a vs. c 0.007
PLT (10xmm³)	272.3±99.2	327.2±218.1	232.8±45.4	0.548
Glucose (mg/dL)	122.5±51.8	91.1±20.1	89.3±12.5	0.170
Urea (mg/dL)	30.9±20.4	17.4±5.7	18.3±5.9	a vs. b 0.040 a vs. c 0.027
Creatinin (mg/dL)	0.7±0.3	1.0±1.1	0.5±0.2	a vs. c 0.009
LDH (U/L)	804.9±1389	582.8±510.8	269.7±90.4	b vs. c 0.005
PT (seconds)	15.2±3.3	11.5±1.1	11±0.4	a vs. b 0.011 a vs. c 0.0002
PTT (seconds)	31.2±4.6	30.9±4	29.5±3.3	0.595
D-Dimer (ng/mL)	3.9±6.9	1513±1474	3215±1247	a vs. b 0.028 a vs. c <0.0001
Fibrinogen (mg/dL)	662.7±167.5	693.9±186.3	566.2±103.4	0.195
Oxygen saturation (%)	88.4±13.3	91.1±5.6	98.5±0.5	0.049
Diabetes				
Gestational	2	3	1	0.614
Type II				
Hypertension	1	2	0	0.375

Obesity	5	6	0	0.037
Gestational age (Weeks)	--	31.4±5.7	35.3±4.8	0.069
1st trimester	--	0	0	ns
2nd trimester	--	2	1	ns
3rd trimester	--	13	12	ns

Non-Pregnant COVID-19+ (NP-COVID-19+), Pregnant-COVID-19+ (P-COVID-19+), Pregnant-COVID-19- (P-COVID-19-). BMI; Body Mass Index. NLR; Neutrophil/Lymphocyte Ratio. Kruskal-Wallis test and Dunn's multiple comparisons test. Significant $p < 0.05$. Media±SD.

Table 2 shows the frequency of symptoms exhibited by patients with and without COVID-19. Despite gestation, patients with COVID-19 had a similar frequency of symptoms such as cough, myalgia, arthritis and anosmia. The most frequent symptoms in pregnant patients with COVID-19 were: cough, myalgia, and arthralgia.

Table 2. Frequency of COVID-19 signs and symptoms.

	NP-COVID-19 + (n=15)a	P-COVID-19 + (n=13)b	P-COVID-19 - (n=12)c	<i>p</i>
Cough	10	9	0	0.001
Rhinorrhea	4	6	0	0.038
Odynophagia	5	3	0	0.092
Myalgia	10	8	0	0.001
Arthralgia	7	7	0	0.012
Anosmia	2	1	0	0.417
Dyspnea	11	6	0	0.0006
Diarrhea	3	1	0	0.202

Non-Pregnant COVID-19+ (NP-COVID-19+), Pregnant-COVID-19+ (P-COVID-19+), Pregnant-COVID-19- (P-COVID-19-). Fisher's exact test. Significant $p < 0.05$.

Cellular immune response is essential against SARS-CoV-2 infection. Using flow cytometry, the proportion of leukocytes with an activated phenotype (HLA-DR+ or CD69+) or inflammatory regulators (CD39+ or CD73+) was determined in peripheral blood samples from the three groups by phenotyping, as described in the methods, and were compared among each other. Figure 1 shows the lower proportion of monocytes

228 HLA-DR⁺ found in P-COVID-19⁺ compared to P-COVID-19⁻ patients (p=0.006).
 229 Along the same line, a lower percentage of monocytes HLA-DR⁺ was observed in NP-
 230 COVID-19⁺ than in P-COVID-19⁻ group (p=0.0003), while NP-COVID-19⁺ and P-
 231 COVID-19⁺ show similar percentage of monocytes HLA-DR⁺. In contrast, the
 232 percentage of CD4 or CD8 T lymphocytes that express HLA-DR or the early activation
 233 marker (CD69) were similar among groups (Table S2).
 234 Regarding CD39, the percentage of monocytes CD39⁺ was lower in the NP-COVID-
 235 19⁺ than in the P-COVID-19⁺ group (p=0.004), a lower percentage was noticed in NP-
 236 COVID-19⁺ than in P-COVID-19⁻ group; however, this difference was not statistically
 237 significant (p = 0.663). A tendency in P-COVID-19⁺ women to express higher
 238 percentage of monocytes CD39⁺ compared to non-infected gestating women (p=0.084)
 239 was observed. CD39 expression was furthermore determine in B and T lymphocytes,
 240 noticing a higher percentage of B CD39⁺ cells in P-COVID-19⁺ and P-COVID-19⁻
 241 compared to NP-COVID-19⁺ group, but these differences were not statistically
 242 significant (p=0.127, p=0.487, respectively). On the other hand, T CD39⁺ cells are
 243 higher in NP-COVID-19⁺ than in P-COVID-19⁺ or P-COVID-19⁻ groups, although
 244 these differences were not significant (p=0.201, p=0.057 respectively). With respect to
 245 CD73, it was found that monocytes CD73⁺ reached a higher percentage in NP-COVID-
 246 19⁺ than in P-COVID-19⁺ group (p=0.029), while, the NP-COVID-19⁺ and P-COVID-
 247 19⁻ show a very similar percentage of monocytes CD73⁺ (p> 0.999). Despite pregnancy
 248 or COVID-19 similar percentages of CD73⁺ in B cells were detected. In contrast, the
 249 percentage of T CD73⁺ cells were lower in NP-COVID-19⁺ than in P-COVID-19⁻
 250 (p=0.038), but similarly low between COVID-19⁺ women regardless of their
 251 gestational status (p=0.227).

252

253

254

255

256

257

258

259

260

Figure 1. Surface marker on leukocytes. Whole blood cells were immunophenotype as described in methods. Results are expressed as mean±SD. Significance value was $p<0.05$. Kruskal-Wallis and Dunn's multiple comparisons test was calculated. Non-Pregnant COVID-19 positive (NP-COVID-19+, n=4-9). Pregnant-COVID-19 positive (P-COVID-19+, n=10-15). Pregnant-COVID-19 negative (P-COVID-19-, n=12-13). Dot line indicates the percentage of monocytes, B and T cells that constitutively express CD39 (26).

261

262

263

264

265

266

267

268

269

270

271

The proportion of lymphocytes and monocytes that synthesize cytokines IL-6, IFN- γ or IL-1 β was determined in P-COVID-19+ patients. Whole blood samples were cultivated 4 hours in absence or presence of polyclonal stimuli (LPS 250 ng/mL, PMA/Ion, 50ng/mL/1mg/mL) or human rIL-6 (100 ng/mL). Figure 2 shows the results of this functional assay. The percentage of CD4 or CD8 T lymphocytes expressing IL-6 or IFN- γ was less than 5% in the groups (Figure 2a, d, g, j), and human rIL-6 did not increase this percentage in CD4 or CD8 T lymphocytes (Figure 2b, e, h, k). The stimulus with PMA/Ion did increase the percentage of CD4 IL-6+ T lymphocytes in the P-COVID-19+ group with respects to the P-COVID-19- group. However, this effect was not seen in the CD8+ IL-6+ T lymphocytes (Figure 2c, i). In addition, PMA/Ion stimulus increased the percentage of CD4 and CD8 IFN- γ + cells in total blood of

272 pregnant women with and without COVID-19 (Figure 2f, l), but statistical significance
 273 is only reached in CD8 IFN- γ ⁺ T lymphocytes between the P-COVID-19⁺ and P-
 274 COVID-19⁻ groups ($p=0.019$, Figure 2l).

275 By the same token, the percentage of monocytes IL-1⁺ or IL-6⁺ is less than 10% in the
 276 groups (Figure 2m, p). The stimulus with human rIL-6 only increased the percentage of
 277 monocytes IL-6⁺ in the P-COVID-19⁻ group with respect to P-COVID-19⁺ (Figure 2q),
 278 but the percentage of monocytes IL-1⁺ was similar among groups (Figure 2n).

279 Incubation with LPS increased the proportion of monocytes IL-1⁺ and IL-6⁺ in the
 280 three groups (Figure 2o, r), with no significant differences among groups. A lower
 281 percentage of monocytes IL-1⁺ was observed in pregnant women with and without
 282 COVID-19 than in NP-COVID-19⁺ (Figure 2o, $p=0.314$ and $p=0.213$ respectively). In
 283 addition, the percentage of monocytes IL-6⁺ in patients with COVID-19⁺ with and
 284 without pregnancy was similar (Figure 2r). After the LPS challenge, we documented a
 285 lower percentage of monocytes IL-6⁺ in P-COVID-19⁻ than in P-COVID-19⁺ group,
 286 even so, this difference is not statistically significant ($p=0.724$).

287

Figure 2. Percentage of cytokine-positive leukocytes. Whole blood cells were immunophenotype as described in methods. Results are expressed as mean±SD. Significance value was $p<0.05$. Kruskal-Wallis and Dunn's multiple comparisons test was calculated. Non-Pregnant COVID-19 positive (NP-COVID-19+, n=5-6). Pregnant-COVID-19 positive (P-COVID-19+, n=12-15). Pregnant-COVID-19 negative (P-COVID-19-, n=12-13).

To determine the serum concentration of cytokine/chemokine in pregnant women with COVID-19+, samples were collected and compared with controls (NP-COVID-19+ and P-COVID-19-). The MIP1b, TNF- α , IL-6 and IL-4 concentration is higher in P-

COVID-19+ than in P-COVID-19- (Figure 3a, b, d, e). Also, the TNF and IL-4
concentration is higher in P-COVID-19+ than in NP-COVID-19+ (Figure 3d, e). Other
cytokine/chemokine show higher concentration in P-COVID-19+ than in P-COVID-19-
, such as CXCL10 (IP10) and IL-2, although these do not reach a statistically significant
difference (Figure 3c and f, $p = 0.456$, and $p=0.447$, respectively). Figure S1 shows
other cytokine/chemokine that show similar concentration between and among groups,
these includes CXCL8, CCL11, CCL17, CCL2, CCL5, CCL3, CXCL9, CXCL5,
CCL23, CXCL1, CXCL11, IL-17a, IFN- γ and IL-10.

Figure 3. Cytokine/Chemokine serum concentration. Serum was isolated and cytokine/chemokines concentration was determined using bead-based immunoassays as described in methods. Results are expressed as mean $\pm$ SD. Significance value was $p<0.05$. Kruskal-Wallis and Dunn's multiple comparisons

test was calculated. Non-Pregnant COVID-19 positive (NP-COVID-19+, n=13). Pregnant-COVID-19 positive (P-COVID-19+, n=14-15). Pregnant-COVID-19 negative (P-COVID-19-, n=13).

To know whether leukocytes from pregnant women with COVID-19 can be activated by polyclonal confrontation and lead to cytokine/chemokine response, whole blood was challenged; Figure 4 shows the concentration in supernatant. After 4 hours of culture without stimulation (whole blood only), the concentration of TNF- α , IFN- γ , CCL3, CCL4, IL-17a, CCL23, CXCL8 and IL-10 was similar among groups. Human rIL-6 induced a higher concentration of TNF- α , CCL3 and CCL4 (Figure 4e, f, d, h), but only TNF- α and CCL3 reached a difference statistically significant (Figure 4a, b). Also, LPS induced a higher concentration of TNF- α , CCL3, CCL4, CCL23 and CXCL8 in all groups, these differences reached high significance ($p < 0.0001$) when contrasted with their respective pair without stimulus (in example; NP-COVID-19+ whole blood vs. P-COVID-19+ LPS). Finally, the stimulation with PMA/Ion induced a higher concentration of CCL3, CCL4, IL-17a, CCL23, CXCL-8 and IL-10 in all groups rather than in their respective pair without stimulus (in example; NP-COVID-19+ WB vs. P-COVID-19+ PMA/Ion). The PMA/Ion did not induce an increase IFN- γ response in all groups, especially in NP-COVID-19+ group, however, the IFN- γ concentration was higher in the pregnancy groups with and without COVID-19 compared to NP-COVID-19+ group, although no statistically significant difference was achieved ($p > 0.9$, $p > 0.9$ respectively). Figure S2 shows that the polyclonal stimulus did not induce an increase response of CXCL10, CCL11, CCL17, CCL2, CCL5, CXCL9, CXCL5, CXCL1, CXCL11, IL-10, IL-4 and IL-2.

Fig 4. Cytokine/Chemokine response after 4 hours of culture with polyclonal stimulus in pregnant and non-pregnant women with or without COVID-19. Supernatant was collected and cytokines/chemokines concentration was determined using bead-based immunoassays as described in methods. Results are expressed as mean±SD. Significance value was $p<0.05$. Kruskal-Wallis and Dunn's multiple comparisons test was calculated. Non-Pregnant COVID-19 positive (NP-COVID-19+, n=3). Pregnant-COVID-19 positive (P-COVID-19+, n=8-10). Pregnant-COVID-19 negative (P-COVID-19-, n=12). WB, Whole Blood.

Discussion

During pregnancy, the immune system is highly regulated. Multiple mechanisms of immune tolerance develop during gestation, and favor physiological progress in reproduction (6). Any viral infection poses a high risk of embryo/fetal-maternal morbidity, as a result of deregulated cellular and humoral immune response immunity, especially during SARS-CoV-2 infection. Villar et al, reported a greater probability of morbidity and mortality in pregnant women with COVID-19 than in pregnant women

without the disease (2). However, how the immune response is involved is unknown in great detail. Herein we explored certain cellular and humoral characteristics that may enhance the understanding of the immuno-pathophysiology in pregnant women with COVID-19.

Pregnant women with COVID-19 were analyzed and compared with non-pregnant women with COVID-19 or those during physiological pregnancy. NP-COVID-19+ and P-COVID-19+ groups were similar in several clinical characteristics such as, BMI, respiratory and heart rate, temperature, MAP, hemoglobin, total platelet count, serum glucose, serum creatinine, LDH and fibrinogen (Table 1). These results indicate that the series of cases analyzed had comparable clinical status. However, some differences between non-pregnant and pregnant women to highlight are: a higher serum urea concentration, the longer PT time and the lower concentration of D-Dimer in NP-COVID-19+ than in P-COVID-19+ or P-COVID-19-. Such differences could be due to the physiological change in the coagulation system during pregnancy (27), and not due to the SARS-CoV-2 infection, moreover, there is a very few reports of COVID-19 coagulopathy during pregnancy(28). A high D-Dimer concentration has been previously reported in the general population as well as in pregnant women with COVID-19 correlating its high levels with fatal outcomes (29-31). Interestingly, within this analysis there was no higher concentration of D-Dimer in P-COVID-19+ compared with P-COVID-19- patients suggesting that, unlike in the general population, D-Dimer concentrations in pregnant women are not necessarily indicative of severity or thromboembolic risk but rather a physiological state of gestation by itself (32). It is necessary to increase the number within a longitudinal study to assess the usefulness of D-Dimer concentration as a severity predictor factor in pregnant COVID-19+ women.

375 Additionally, the frequency of symptoms was similar between NP-COVID-19 and P-
376 COVID-19 (Table 2), indicating a homogeneous clinical presentation, allowing the
377 identification of cellular and humoral characteristics in response against COVID-19 in
378 the presence or absence of pregnancy.

379 Our study shows that the percentage of monocytes HLA-DR+ is lower in COVID-19+
380 women with and without pregnancy than in P-COVID-19- (Fig 1). Also, a lower
381 percentage has been observed in septic patients with critical condition or fatal outcome
382 (33, 34), suggesting that this characteristic could be a helpful biomarker in COVID-19.

383 The lower percentage of monocytes HLA-DR+ in COVID-19 could be the way to
384 downregulate the immune response by SARS-CoV-2 and to evade the immunity, or the
385 way that the immune response control activation and avoid over-stimulation. Our results
386 suggest that COVID-19 does not accentuate the low percentage of monocytes HLA-
387 DR+, which would indicate that pregnancy does not limit the activation of monocytes in
388 peripheral blood upon a SARS-CoV-2 infection. More analysis is required to know the
389 biological significance of lower percentage of monocytes HLA-DR+ in COVID-19.

390 Furthermore, a high percentage of lymphocytes CD69+ is reached in AH1N1 influenza,
391 another viral challenge that leads to unregulated inflammation in pregnant women (35).

392 Likewise, we found a higher percentage of CD69+ cells in both CD4 and CD8 cells in
393 P-COVID-19+ than in NP-COVID-19+ and P-COVID-19- without reaching a statistical
394 significance (Table S2). This indicates a higher level of activation despite the multiple
395 mechanisms to ensure an immunotolerance during pregnancy.

396 The expression of CD39 and CD73 on leukocytes may be an important mechanism for
397 resolving SARS-CoV-2 infection and COVID-19 disease. CD39 and CD73 are
398 ectoenzymes that sequentially metabolize ATP to adenosine (26, 36), thus controlling

inflammation through this alarmine, leading to an adenosine induced anti-inflammatory response (26). Pregnant women with or without COVID-19 maintain higher percentages of monocytes CD39+, and lower percentage of CD73+ than in NP-COVID-19+ (Fig 1), suggesting that pregnant women control inflammation through monocytes CD39+/CD73+. These could be a potential marker to monitor the evolution of COVID-19. The function of CD39/CD73 is not limited to monocytes, however, our results indicate that the percentage of B or T cells CD39+ or CD73+ is not significantly modified by the effects of pregnancy or COVID-19 infection (Figure 1).

Activated leukocytes are a potential source of pro-inflammatory or regulatory cytokines in peripheral blood of COVID-19 patients. We determined the percentage of leukocytes IL-6+, IFN- γ + or IL-1 β + after 4 hours of culture with or without polyclonal stimulation. Lymphocytes T CD4+ IL-6+ or IFN- γ +, CD8+IL-6+ or IFN- γ + and monocytes IL-1 β + or IL-6+ did not reach more than 5% of circulating cells, indicating a low baseline of circulating cytokine producing leukocytes. After being stimulated with human rIL6, there was no significant increase of IL-1 β , IL-6 or IFN- γ producers in lymphocytes and monocytes, indicating that the IL-6 in serum of COVID-19 patients could have a limited stimulus to increase the synthesis of pro-inflammatory cytokines from circulating leukocytes. Whole blood stimulation LPS or PMA/Ion increases the percentage of lymphocytes T CD4+ and CD8+ and monocytes IFN- γ + or IL-1 β + and IL-6+, indicating that these leukocytes are not anergic and retain the ability to synthesize cytokines both in the presence and absence of pregnancy and COVID-19. However, there is a trend to increase the percentage of monocytes IL-6+ and decrease the percentage of lymphocytes CD4+IFN- γ + and CD8+IFN- γ + in patients with COVID-19.

422 This suggests that both women with or without pregnancy develop quite similar
 423 defenses to face COVID-19, increasing IL-6 and limiting IFN- γ response.

424 The cytokine storm induced by COVID-19 could be greater in pregnant women, our
 425 study shows that some cytokines (TNF- α , IL-6 and CCL3) reach a higher concentration
 426 in serum of NP-COVID-19+ than in P-COVID-19+ patients, although it was only
 427 significantly higher for TNF- α (Figure 3a). Interestingly, we also found a highest
 428 concentration of IL-4 in the P-COVID-19+ group with a statistically difference in NP-
 429 COVID-19+ ($p=0.01$) and P-COVID-19- ($p=0.01$). Despite pregnancy, results indicate a
 430 similar pro-inflammatory profile in COVID-19+ patients, which could be regulated by
 431 IL-4 in pregnant women. Some reports show that the concentration of CXCL10
 432 chemokine is associated with a poor prognosis in COVID-19+ patients (20). In contrast,
 433 this study found a lower concentration in P-COVID-19+ patients, which would favor
 434 the immune response in pregnancy.

435 After analysis of the basal and leukocyte response to polyclonal stimulation, the basal
 436 concentration of cytokines is similar among groups (Figure 4), indicating that, despite
 437 COVID-19, peripheral leukocytes have a similar potential to produce cytokines. This
 438 suggests that production of cytokines in COVID-19 could depend of an alternate source
 439 such as endothelial cells. Human rIL-6 stimulus caused an increase in some cytokines
 440 such as TNF- α , CCL3 and CCL4, indicating that IL-6 favors synthesis of some
 441 cytokines but not an entire cytokine storm. In addition, the response in COVID-19 to
 442 IL-6 seems to be similar in the presence or absence of pregnancy, indicating that
 443 pregnancy not necessarily aggravates the pro-inflammatory responses in COVID-19. To
 444 explore if leukocytes response is limited by COVID-19, we performed a LPS or
 445 PMA/Ion stimulus, resulting in a clear pro-inflammatory response with cytokines such

as, TNF- α , CCL3, CCL4, IL-17a, CCL23 and CXCL8 in supernatant, indicating that leukocytes are not anergic. It has been proposed that an immunosuppression rather than a hyper-cytokine response in COVID-19 could support the pathophysiology (37). However, these results indicate that peripheral blood leukocytes from pregnant women with COVID are capable of expressing a similar response as a healthy pregnant woman. The main limitation of the present study is the compact number of patients. A greater number of observations are required to reach a final and more representative conclusion. However, the reproducibility and consistency of these results back our analysis. Pregnant women with or without COVID-19 control inflammation through monocytes CD39+/CD73+ maintaining higher percentages of monocytes CD39+ and lower percentage of CD73+ than NP-COVID-19+ patients. Hence, CD39/CD73 is a potential marker to monitor the evolution of COVID-19. On the other hand, unlike in the general population, D-Dimer concentrations in pregnant women are not necessarily indicative of severity or thromboembolic risk but rather a physiological state of gestation by itself. These findings help the focus for future studies on the immune profile in pregnant women with COVID-19, provides evidence about the functional immunological profile in pregnant women with COVID-19 and enriches the knowledge on the immune response that occurs during pregnancy.

464

465 Contributors

466 ACV and CLM conceived and designed the study, and contributed to data analysis. ACV
467 wrote the first version of manuscript. MGE, JCBG, LAAP, EFO, OMA, GMLGA,
468 contributed with a critical revision of the report. MGE, JCBG, BZB, RCdLB, AHVC,
469 AEP, RRMdO, FCS, LARG, GFP, OMA, GMLGA contributed with the clinical
470 evaluation of patients and supervision of medical treatments and patient care. ACV,
471 LAAP, EFO, GLCR, PMC, MTGR, JLPC, VRA, RLMS, ACC, ESR, MESR and DSM,
472 contributed with data acquisition, analysis and/or interpretation. All authors reviewed the
473 final version. CLM reviewed and approved the final version.

474

475 Acknowledgements

This project was supported by the Mexican National Research Council (CONACyT), (Project No. 313494 awarded to CLM). The authors extend a gratitude to the staff at the Specialties Hospital, National Medical Center "XXI Century", Gynecology & Obstetrics Department in the General Hospital of Mexico "Dr. Eduardo Liceaga" and Gynecology & Obstetric Hospital No. 4 UMAE "Dr. Luis Castelazo Ayala".

Declaration of interests

All authors declare no competing interests.

References

1. Berhan Y. What immunological and hormonal protective factors lower the risk of COVID-19 related deaths in pregnant women? *J Reprod Immunol.* 2020;142:103180.
2. Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. *JAMA Pediatr.* 2021.
3. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(44):1641-7.
4. Delahoy MJ, Whitaker M, O'Halloran A, Chai SJ, Kirley PD, Alden N, et al. Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 - COVID-NET, 13 States, March 1-August 22, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(38):1347-54.
5. PrabhuDas M, Piper JM, Jean-Philippe P, Lachowicz-Scroggins M. Immune Regulation, Maternal Infection, Vaccination, and Pregnancy Outcome. *J Womens Health (Larchmt).* 2021;30(2):199-206.
6. Arck PC, Hecher K. Fetomaternal immune cross-talk and its consequences for maternal and offspring's health. *Nature medicine.* 2013;19(5):548-56.
7. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Med Infect Dis.* 2020;34:101623.
8. Petrakis D, Margina D, Tsarouhas K, Tekos F, Stan M, Nikitovic D, et al. Obesity a risk factor for increased COVID19 prevalence, severity and lethality (Review). *Mol Med Rep.* 2020;22(1):9-19.
9. Pettiroso E, Giles M, Cole S, Rees M. COVID-19 and pregnancy: A review of clinical characteristics, obstetric outcomes and vertical transmission. *Aust N Z J Obstet Gynaecol.* 2020;60(5):640-59.
10. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM.* 2020;2(2):100107.
11. Mardani R, Ahmadi Vasmehjani A, Zali F, Gholami A, Mousavi Nasab SD, Kaghazian H, et al. Laboratory Parameters in Detection of COVID-19 Patients with

522 Positive RT-PCR; a Diagnostic Accuracy Study. *Arch Acad Emerg Med.*
523 2020;8(1):e43.

524 12. Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung
525 pathology of fatal severe acute respiratory syndrome. *Lancet.* 2003;361(9371):1773-8.

526 13. Li T, Qiu Z, Zhang L, Han Y, He W, Liu Z, et al. Significant changes of
527 peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. *J*
528 *Infect Dis.* 2004;189(4):648-51.

529 14. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, et al. Lymphopenia is
530 associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic
531 review and meta-analysis. *Int J Infect Dis.* 2020;96:131-5.

532 15. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-
533 19): systematic review and meta-analysis. *J Intensive Care.* 2020;8:36.

534 16. Law HK, Cheung CY, Ng HY, Sia SF, Chan YO, Luk W, et al. Chemokine up-
535 regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells.
536 *Blood.* 2005;106(7):2366-74.

537 17. Chien JY, Hsueh PR, Cheng WC, Yu CJ, Yang PC. Temporal changes in
538 cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory
539 syndrome. *Respirology.* 2006;11(6):715-22.

540 18. Chang YJ, Liu CY, Chiang BL, Chao YC, Chen CC. Induction of IL-8 release in
541 lung cells via activator protein-1 by recombinant baculovirus displaying severe acute
542 respiratory syndrome-coronavirus spike proteins: identification of two functional
543 regions. *J Immunol.* 2004;173(12):7602-14.

544 19. Chen IY, Chang SC, Wu HY, Yu TC, Wei WC, Lin S, et al. Upregulation of the
545 chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus
546 spike-ACE2 signaling pathway. *J Virol.* 2010;84(15):7703-12.

547 20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients
548 infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497-
549 506.

550 21. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-
551 Rodriguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease.
552 *Cytokine Growth Factor Rev.* 2020;54:62-75.

553 22. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant
554 protein-1 (MCP-1): an overview. *J Interferon Cytokine Res.* 2009;29(6):313-26.

555 23. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. Interleukin-1beta
556 causes pulmonary inflammation, emphysema, and airway remodeling in the adult
557 murine lung. *Am J Respir Cell Mol Biol.* 2005;32(4):311-8.

558 24. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and
559 adaptive immune responses. *Adv Immunol.* 2007;96:41-101.

560 25. Breslin N, Baptiste C, Gyamfi-Bannerman C, Miller R, Martinez R, Bernstein
561 K, et al. COVID-19 infection among asymptomatic and symptomatic pregnant women:
562 Two weeks of confirmed presentations to an affiliated pair of New York City hospitals.
563 *Am J Obstet Gynecol MFM.* 2020:100118.

564 26. Zhao H, Bo C, Kang Y, Li H. What Else Can CD39 Tell Us? *Front Immunol.*
565 2017;8:727.

566 27. Thornton P, Douglas J. Coagulation in pregnancy. *Best Pract Res Clin Obstet*
567 *Gynaecol.* 2010;24(3):339-52.

568 28. Kadir RA, Kobayashi T, Iba T, Erez O, Thachil J, Kazi S, et al. COVID-19
569 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH

570 registry-Communication from the ISTH SSC for Women's Health. *J Thromb Haemost.*
571 2020;18(11):3086-98.

572 29. Vidali S, Morosetti D, Cossu E, Luisi MLE, Pancani S, Semeraro V, et al. D-
573 dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review. *ERJ*
574 *Open Res.* 2020;6(2).

575 30. Gong X, Song L, Li H, Li L, Jin W, Yu K, et al. CT characteristics and
576 diagnostic value of COVID-19 in pregnancy. *PLoS One.* 2020;15(7):e0235134.

577 31. Wang Z, Wang Z, Xiong G. Clinical characteristics and laboratory results of
578 pregnant women with COVID-19 in Wuhan, China. *Int J Gynaecol Obstet.*
579 2020;150(3):312-7.

580 32. Hedengran KK, Andersen MR, Stender S, Szecsi PB. Large D-Dimer
581 Fluctuation in Normal Pregnancy: A Longitudinal Cohort Study of 4,117 Samples from
582 714 Healthy Danish Women. *Obstet Gynecol Int.* 2016;2016:3561675.

583 33. Ferat-Orsorio E, Esquivel-Callejas N, Wong-Baeza I, Aduna-Vicente R, Arriaga-
584 Pizano L, Sanchez-Fernandez P, et al. The increased expression of TREM-1 on
585 monocytes is associated with infectious and noninfectious inflammatory processes. *J*
586 *Surg Res.* 2008;150(1):110-7.

587 34. Ferat-Orsorio E, Wong-Baeza I, Esquivel-Callejas N, Figueroa-Figueroa S,
588 Duarte-Rojo A, Guzman-Valdivia-Gomez G, et al. Triggering receptor expressed on
589 myeloid cells-1 expression on monocytes is associated with inflammation but not with
590 infection in acute pancreatitis. *Crit Care.* 2009;13(3):R69.

591 35. Cerbulo-Vazquez A, Figueroa-Damian R, Arriaga-Pizano LA, Hernandez-
592 Andrade E, Mancilla-Herrera I, Flores-Mejia LA, et al. Pregnant women infected with
593 pandemic H1N1pdm2009 influenza virus displayed overproduction of peripheral blood
594 CD69+ lymphocytes and increased levels of serum cytokines. *PLoS One.*
595 2014;9(9):e107900.

596 36. Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and
597 inflammation. *Trends Mol Med.* 2013;19(6):355-67.

598 37. Remy KE, Mazer M, Striker DA, Ellebedy AH, Walton AH, Unsinger J, et al.
599 Severe immunosuppression and not a cytokine storm characterizes COVID-19
600 infections. *JCI Insight.* 2020;5(17).

601

602

Table S1. Percentage of leukocytes after 4 hours of medium culture in pregnant and non-pregnant women with or without COVID-19

Leukocyte (%)	NP-COVID-19+ (n=6-9)a	P-COVID-19+ (n=15)b	P-COVID-19- (n=13)c	<i>p</i>
Lymphocyte	15.8±11.4	19.4±9.5	28.2±7.8	0.031
T cell CD4+	55.3±8.4	54.5±8.9	59.7±7.4	0.206
T cell CD8+	35.5±9.3	37.7±9.9	34.1±6.0	0.533
T cell CD4+CD8+	0.6±0.4	1.2±1.9	0.9±1.2	0.801
Monocytes	2.4±1.3	2.5±1.7	3.4±1.8	0.359
Granulocytes	81.5±12.5	77.8±10.4	68.1±9.4	0.058

Non-Pregnant COVID-19+ (NP-COVID-19+), Pregnant-COVID-19+ (P-COVID-19+), Pregnant-COVID-19- (P-COVID-19-). Fisher's exact test. Significant $p < 0.05$. Viability >90%.

Table S2. Surface of activation markers on leukocytes in pregnant and non-pregnant women with or without COVID-19

Leukocyte (%)	NP-COVID-19+ (n=4-9)a	P-COVID-19+ (n=10-15)b	P-COVID-19- (n=12-13)c	<i>p</i>
T cell CD4+CD69+	0.9±0.4	4.9±13.8	0.4±0.2	a vs. c 0.020
T cell CD8+CD69+	5.1±4.2	5.3±4.6	2.4±1.3	0.076
T cell CD4+HLA-DR+	5.2±2.5	5.4±3.6	6.2±2.0	0.509
T cell CD8+HLA-DR+	10.5±9.5	11.2±7.2	14.8±6.1	0.121

Non-Pregnant COVID-19+ (NP-COVID-19+), Pregnant-COVID-19+ (P-COVID-19+), Pregnant-COVID-19- (P-COVID-19-). BMI; Body Mass Index. NLR; Neutrophil/Lymphocyte Ratio. Kruskal-Wallis test. Significant $p < 0.05$. Media±SD.

634 **Table S3. Cytokine-positive leukocyte percentage after 4 hours of polyclonal**
635 **stimulus in pregnant and non-pregnant women with or without COVID-19**

Leukocyte (%)	NP-COVID-19 + (n=5-6)a	P-COVID-19 + (n=12-15)b	P-COVID-19 - (n=13)c	<i>p</i>
T cell CD4+TNF+				
Medium	0.4±0.2	0.9±1.2	0.7±1.4	0.222
IL-6	3.5±6	0.4±0.4	0.6±0.6	0.290
PMA/Ion	8.4±7.3	9.9±8.2	14.6±16.7	0.692
T cell CD8+TNF+				
Medium	1.4±1.0	3.7±8.1	0.5±0.7	0.118
IL-6	2.3±4.3	1.3±3.0	0.6±1.0	0.337
PMA/Ion	4.6±2.5	8.3±8.1	11.2±9.6	0.210
Monocyte TNF+				
Medium	5.4±5.2	3.7±4.1	1.9±2.1	0.218
IL-6	4.6±2.7	4.5±4.8	4.4±3.2	0.814
LPS	38.6±30.1	43.0±28.9	21.2±12.9	0.105
Monocyte IL-8+				
Medium	14.1±10.6	13.9±9.6	22.3±12.5	0.165
IL-6	24.3±15.6	17.6±12.6	26.1±14.7	0.274
LPS	44.4±35.7	50.4±26.7	39.6±16.2	0.540

636 NP-COVID-19+; Non-Pregnant COVID-19+. P-COVID-19+; Pregnant-COVID-19+. P-COVID-19-;
637 Pregnant-COVID-19-. Fisher's exact test. Significant *p*<0.05.
638
639
640
641
642
643
644

Figure S1. Similar Cytokine/Chemokine serum concentration in pregnant and non-pregnant women with or without COVID-19. Serum was isolated and cytokine/chemokines concentration was determined using bead-based immunoassays as described in methods. Results are expressed as mean±SD. Significance value was $p<0.05$. Kruskal-Wallis and Dunn's multiple comparisons test was calculated. Non-Pregnant COVID-19 positive (NP-COVID-19+, n=13). Pregnant-COVID-19 positive (P-COVID-19+, n=15-16). Pregnant-COVID-19 negative (P-COVID-19-, n=13).

Figure S2. Similar Cytokine/Chemokine response after 4 hours of culture with polyclonal stimulus in pregnant and non-pregnant women with or without COVID-19. Supernatant was collected and cytokines/ chemokines concentration was determined using bead-based immunoassays as described in methods. Results are expressed as mean±SD. Significance value was $p<0.05$. Kruskal-Wallis and Dunn's multiple comparisons test was calculated. Non-Pregnant COVID-19 positive (NP-COVID-19+, n=3). Pregnant-COVID-19 positive (P-COVID-19+, n=9-10). Pregnant-COVID-19 negative (P-COVID-19-, n=12). WB, Whole Blood.